Gilead's oral drug succeeds in mid-stage inflammatory bowel disease trial

On October 19, 2026, Gilead Sciences announced positive Phase 2 trial results for emvistegrast, an experimental once-daily oral drug targeting the α4β7 integrin pathway in adults with moderate to severe ulcerative colitis. After 12 weeks of treatment with a 200 mg daily dose, 66% of patients saw symptom improvement and 31% achieved clinical remission, significantly outperforming placebo and exceeding analyst expectations. Gilead plans to launch a Phase 3 study in 2027.

Phase 2 trial efficacy results

• ▪Gilead Sciences announced on October 19, 2026, that its experimental once-daily oral drug emvistegrast met its primary endpoint in a Phase 2 trial for adults with moderate to severe ulcerative colitis
• ▪The 23% placebo-adjusted clinical remission rate achieved by emvistegrast in Gilead Sciences' Phase 2 ulcerative colitis trial exceeded Wall Street analyst expectations
• ▪In Gilead Sciences' Phase 2 trial, 66% of ulcerative colitis patients taking a 200 milligram daily dose of emvistegrast achieved symptom improvement compared to 37% for placebo, and 31% achieved clinical remission compared to 8% for placebo after 12 weeks

Analyst reactions and future plans

• ▪Gilead Sciences plans to initiate a late-stage Phase 3 monotherapy study of emvistegrast in 2027
• ▪BMO Capital Markets analysts stated that the Phase 2 ulcerative colitis trial data establishes emvistegrast as a credible oral α4β7 integrin option and serves as an incremental positive for Gilead Sciences' inflammatory strategy

Mechanism of action and disease context

• ▪Gilead Sciences designed emvistegrast to block the α4β7 integrin pathway, an established biological target for treating inflammatory bowel disease
• ▪Swati Tole, Gilead Sciences' senior vice president overseeing clinical development of inflammatory disease medicines, stated that a majority of patients with inflammatory bowel disease fail to achieve clinical remission on existing therapies
• ▪Ulcerative colitis is a chronic inflammatory condition causing inflammation and ulcers in the digestive tract of affected patients